Press releases

Revenue of $5.5 billion increased 10.4% as reported, 8.5% adjusted FXN and 3.0% organic GAAP and adjusted diluted EPS grew to $2.00 and $3.68, respectively GAAP and adjusted gross margin up 160...

New CLIA-Waived Test Delivers Digital Results to Support Timely Clinical Decision-Making FRANKLIN LAKES, N.J., July 30, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement: BD has reached an agreement with the U.S. Securities and Exchange...

Emphasizes Value of Domestic Production of Critical Medical Devices FRANKLIN LAKES, N.J., Aug. 22, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement regarding the March 19, 2024 U.S. Food and Drug Administration...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Dave Hickey has informed the company of his intent to retire from BD, effective...

Company Reinforces its Longstanding Commitment to Help Improve Health Equity and Expand Access to Care Among Vulnerable Populations FRANKLIN LAKES, N.J., Dec. 11, 2023 /PRNewswire/ -- BD (Becton,...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement regarding the U.S. Food and Drug Administration (FDA) Safety...

WASHINGTON, D.C., USA, Nov. 20, 2023 – BD (Becton Dickinson and Company), a leading global medical technology company, and Bio Farma, a state-owned life science company in Indonesia, signed a...

Execution of BD 2025 Strategy Driving Durable, Broad-Based Growth Q4 revenue of $5.1 billion increased 6.8% as reported and 5.9% on a currency-neutral basis Q4 revenue from base business (which...